US Appln. No.: 10/564,706 US Filing Date: 13 January 2006

Case No.: 21172YP

Page No.: 2

### **Listing of Claims**

The listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A compounds compound of the Formula:

$$R^1$$
  $N$   $N$   $R^2$   $R^3$ 

wherein:

R<sup>1</sup> is selected from:

- a) hydrogen,
- b) aryl, heterocycle, C<sub>3</sub>-C<sub>10</sub> cycloalkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, and
- c) C<sub>1</sub>-C<sub>6</sub> alkyl, unsubstituted or substituted with 1 to 5 substituents selected from:
  - 1) aryl, unsubstituted or substituted with 1 to 5 substituents selected from:
    - i) C<sub>1</sub>-C<sub>6</sub> alkyl, unsubstituted or substituted with 1-3 fluoro,
    - ii) C<sub>3</sub>-C<sub>6</sub> cycloalkyl,
    - iii) C<sub>2</sub>-C<sub>6</sub> alkynyl,
    - iv) OR<sup>10</sup>,
    - v) aryl,
    - vi) heterocycle,
    - vii) CN, and
    - viii) halo;
  - 2) heterocycle, unsubstituted or substituted with 1 to 5 substituents selected from:
    - i) C<sub>1</sub>-C<sub>6</sub> alkyl, unsubstituted or substituted with 1-3 fluoro,
    - ii) -OR<sup>10</sup>,
    - iii) aryl, and

US Appln. No.: 10/564,706

US Filing Date: 13 January 2006 Case No.: 21172YP

Page No.: 3

- iv) halo;
- 3) C<sub>3</sub>-C<sub>10</sub> cycloalkyl,
- 4)  $C_2$ - $C_6$  alkenyl,
- 5)  $C_2$ - $C_6$  alkynyl,
- 6)  $-OR^{10}$ ,
- 7)  $-S(O)_m R^{11}$ ,
- 8)  $-NR^6-C(O)R^7$ ,
- 9)  $-C(O)-N(R^6)(R^7)$ ,
- 10) -CN,
- 11)  $-NR^6-C(O)-N(R^6)(R^7)$ ,
- 12)  $-C(O)-OR^{10}$ ,
- 13) halo, and
- 14)  $-N(R^6)(R^7);$

## R<sup>2</sup> is selected from:

- a)  $-NR^6-C(O)R^7$ ,
- b)  $-NR^6-S(O)_2R^7$ , and
- d)-c)  $-NR^6-S(O)^2-N(R^6)(R^7)-NR^6-S(O)_2-N(R^6)(R^7);$

# R³ and R⁴ are independently selected from:

hydrogen, aryl, heterocycle, halo,  $C_1$ - $C_6$  alkyl,  $C_3$ - $C_{10}$  cycloalkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl,  $C_1$ - $C_4$  haloalkyl,  $R^{10}$ O-,  $R^{11}$ S(O)<sub>m</sub>-,  $R^6$ C(O)-NR<sup>7</sup>-, CN, ( $R^6$ )(  $R^7$ )N-C(O)-(NR<sup>6</sup>)-, ( $R^6$ )(  $R^7$ )-N-C(O)-,  $R^{10}$ C(O)-,  $R^{10}$ OC(O)-, and N( $R^6$ )(  $R^7$ ); or

wherein R<sup>3</sup> and R<sup>4</sup> are optionally joined to form a saturated or unsaturated ring, containing 0-3 heteroatoms, wherein said ring is phenyl, pyridyl, pyrimidinyl, pyrazinyl, thiophenyl, furanyl, imidazolyl, thiazolyl, oxazolyl, and triazolyl, as well as partially saturated analogues thereof, said ring optionally substituted with one or more of:

aryl, heterocycle,  $C_1$ - $C_6$  alkyl,  $C_3$ - $C_{10}$  cycloalkyl,  $C_2$ - $C_6$  alkynyl,  $R^{10}$ O-,  $R^{11}$ S(O) <sub>m</sub>-,  $R^6$ C(O)N  $R^7$ -,  $R^6$ S(O)2N $R^7$ - $R^6$ S(O)2N $R^7$ -,  $R^7$ -,  $R^6$ S(O)2N $R^7$ -,  $R^$ 

US Appln. No.: 10/564,706 US Filing Date: 13 January 2006

Case No.: 21172YP

Page No.: 4

R<sup>6</sup> and R<sup>7</sup> are independently selected from hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>10</sub> cycloalkyl, heterocycle, aryl, unsubstituted or substituted withone or more of:

- a) C<sub>1</sub>-C<sub>4</sub> alkyl,
- C<sub>1</sub>-C<sub>4</sub> alkoxy, b)
- aryl or heterocycle, c)
- d) halo,
- -OR<sup>10</sup>, and -N(R<sup>10</sup>)<sub>2</sub>; e)
- f)

wherein R<sup>6</sup> and R<sup>7</sup> may be joined to form a ring;

R<sup>10</sup> is independently selected from hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, -CF<sub>3</sub>, C<sub>3</sub>-C<sub>10</sub> cycloalkyl, benzyl, and aryl;

 $R^{11}$  is independently selected from  $C_1$ - $C_6$  alkyl, and aryl;

m is 0, 1, or 2;

and pharmaceutically acceptable salts and individual diastereomers thereof.

- The compound according to Claim 1, wherein R<sup>1</sup> is -CH<sub>2</sub>-aryl, 2. (Original) unsubstituted or substituted with 1-3 substituents selected from: fluoro, chloro, bromo, iodo and methyl.
- The compound according to Claim 1, wherein R<sup>1</sup> is benzyl, 3. (Original) substituted with 1-3 fluoro.
- The compound according to Claim 1, wherein R<sup>1</sup> is -4. (Original)  $CH_2C(O)OR^{10}$ .
- The compound according to Claim 1, wherein R<sup>1</sup> is -5. (Original)  $CH_2C(O)OC(CH_3)_3$ .

US Appln. No.: 10/564,706 US Filing Date: 13 January 2006 Case No.: 21172YP Page No.: 5

CH₂C(O)NHR	6. <sup>6</sup> .	(Original)	The compound according to Claim 1, wherein R <sup>1</sup> is -
CH <sub>2</sub> C(O)NH(C	7. C <sub>4</sub> -C <sub>10</sub> cy	(Original) cloalkyl).	The compound according to Claim 1, wherein R <sup>1</sup> is -
CH₂C(O)NH-a	8. aryl.	(Original)	The compound according to Claim 1, wherein R <sup>1</sup> is -
$S(O)_2R^7$ .	9.	(Original)	The compound according to Claim 1, wherein $R^2$ is -NR <sup>6</sup> -
	10.	(Original)	The compound according to Claim 1, wherein R <sup>3</sup> is hydrogen.
joined to form	11. a ring se	(Original) elected from: phe	The compound according to Claim 1, wherein R <sup>3</sup> and R <sup>4</sup> are enyl, pyridyl, pyrimidinyl and pyrazinyl.
joined to form	12. a pyridy	(Original) l ring.	The compound according to Claim 1, wherein R <sup>3</sup> and R <sup>4</sup> are
	13.	(Original)	The compound according to Claim 1, wherein R <sup>4</sup> is bromo.
	14.	(Original)	The compound according to Claim 1, wherein $R^4$ is -C(O)OR <sup>10</sup> .
	15.	(Original)	A compound selected from:

US Appln. No.: 10/564,706 US Filing Date: 13 January 2006 Case No.: 21172YP

Page No.: 6

$$\begin{array}{c|c} & & & \\ & & & \\ N & O \\ & & \\ N & O \\ & & \\ OH & O \\ & & \\ OH & O \\ & & \\ CH_3 \\ & & \\ CH_3 \\ & & \\ \end{array}$$

US Appln. No.: 10/564,706 US Filing Date: 13 January 2006 Case No.: 21172YP Page No.: 7

US Appln. No.: 10/564,706

US Filing Date: 13 January 2006 Case No.: 21172YP

Page No.: 8

and pharmaceutically acceptable salts and individual diastereomers thereof.

16. (Original) A pharmaceutical composition which comprises an inert carrier and the compound of Claim 1.

#### 17. (Canceled)

18. (Currently Amended) A method for treating, controlling, ameliorating or reducing the risk of headache, migraine or cluster headache in a mammalian patient in need of such which comprises administering to the patient a therapeutically effective amount of the compound of Claim 1.

### 19 24. (Canceled)

25. (New) The method of claim 18, wherein the headache is migraine headache or cluster headache.